These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Clinical evaluation of cefmenoxime in internal medicine, with special reference to infection associated with hematological disorders].
    Author: Kawamura S, Sakata Y, Chiba Y, Yoshida Y, Kanazawa T, Kawazu S, Tsuge M, Tanabe K, Nara H, Aizawa M.
    Journal: Jpn J Antibiot; 1986 May; 39(5):1250-8. PubMed ID: 3463775.
    Abstract:
    Clinical evaluation of cefmenoxime (CMX, Bestcall) was performed against infections associated with hematological, respiratory tract and other disorders. Clinical effectiveness of CMX against severe infections with hematological disorders including sepsis, pneumonia, pyelitis and so on was 74.4% for good responses and against the respiratory tract infections, 96.2% for good responses was obtained. Neither objective or subjective side effects nor extreme abnormalities in laboratory tests were observed in these patients. It can be concluded, therefore, that CMX is one of the most useful drugs against infectious diseases associated with hematological disorders, respiratory tract and other disorders.
    [Abstract] [Full Text] [Related] [New Search]